Detalhe da pesquisa
1.
Pharmacological disruption of the Notch transcription factor complex.
Proc Natl Acad Sci U S A
; 117(28): 16292-16301, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32601208
2.
Identifying Cell Differentiation in Colorectal Cancer.
Methods Mol Biol
; 2650: 227-233, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310635
3.
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer.
J Vis Exp
; (192)2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36847362
4.
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.
Cell Rep
; 42(8): 112927, 2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537841
5.
The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
Cell Rep
; 41(3): 111430, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261015
6.
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Nat Cancer
; 3(4): 418-436, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35469014
7.
Advanced Colorectal Cancer Orthotopic Patient-Derived Xenograft Models for Cancer and Stem Cell Research.
Methods Mol Biol
; 2171: 321-329, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32705653
8.
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
J Clin Invest
; 128(9): 3887-3905, 2018 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29944140
9.
Tankyrase Inhibition Blocks Wnt/ß-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Clin Cancer Res
; 22(3): 644-56, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26224873
10.
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Clin Cancer Res
; 21(24): 5499-5510, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272063
11.
A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.
Clin Cancer Res
; 19(24): 6787-801, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24170545
12.
ß-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Nat Med
; 18(6): 892-901, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22610277
13.
Vitamin D receptor deficiency enhances Wnt/ß-catenin signaling and tumor burden in colon cancer.
PLoS One
; 6(8): e23524, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21858154